Key Insights: Real-World Evidence for ITP Treatment

Key Insights: Real-World Evidence for ITP Treatment

On-Demand Webcast

David P. Steensma, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Ilene C. Weitz, MD
Keck School of Medicine
University of Southern California
Los Angeles, California


James B. Bussel, MD
Professor Emeritus of Pediatrics
Weill Cornell Medicine
New York, New York

Target Audience

This educational activity is designed for hematologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc) involved and/or interested in the therapeutic management of patients with immune thrombocytopenia purpura (ITP).


Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopenic purpura (ITP), and there remains significant variability in clinical practice patterns for its management. This activity features David P. Steensma, MD and Ilene C. Weitz, MD sharing their insights about data recently released in publication form pertaining to pharmacotherapy for ITP, with a focus on the use of thrombopoietin (TPO) receptor agonists.


Upon successful completion of this educational activity, participants should be better able to:

  1. Describe the rationale for the topic reviewed or study reported in the selected publication
  2. Analyze key points and/or study findings of the selected publication
  3. Devise treatment plans for patients with ITP based on relevant insights shared in the selected publication

Release Date: March 31, 2019

Expiration Date: March 31, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Supported by an educational grant from: Novartis Pharmaceuticals Corporation.



Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Imedex designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 0.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 0.5 contact hours.


This knowledge-based activity (JA0006201-9999-19-022-H01-P) is approved for 0.5 contact hours (0.005 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises James B. Bussel, MD, David P. Steensma, MD, and Ilene C. Weitz, MD; and Chris Bolwell and Monalisa Singh, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

James B. Bussel, MD has served as a consultant for Amgen, argenx, Dova Pharmaceuticals, Momenta Pharaceuticals, Novartis Pharmaceuticals Corporation, Rallybio, Rigel Pharmaceuticals, and UCB and has participated in a speaker's bureau for Novartis Pharmaceuticals Corporation.

David P. Steenma, MD has received research and/or grant support from Aprea, Celgene, H3 Biosciences, Incyte, and Syros, has served as a consultant for Celgene, H3 Biosciences, Janssen and Novartis Pharmaceuticals Corporation, and is a major stock shareholder in Array Biopharma Inc.

Ilene C. Weitz, MD disclosed no relevant financial relationships with any commercial interests.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Monalisa Singh disclosed no relevant financial relationships with any commercial interests.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.